References
- Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar
JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Cosedis
Nielsen J, Curtis AB, Davies DW, Day JD, d’Avila A, Natasja de Groot
NMS, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor
PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M,
Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J,
Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle
L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel
S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P,
Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ,
Yamane T; Document Reviewers:. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert
consensus statement on catheter and surgical ablation of atrial
fibrillation. Europace.
2018;20:e1-e160.
- Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J,
Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hügl BJ,
Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A;
VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted
vitamin K antagonists for catheter ablation in non-valvular atrial
fibrillation. Eur Heart J.
2015;36:1805-11.
- Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser
SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA,
Grimaldi M; RE-CIRCUIT Investigators. Uninterrupted Dabigatran versus
Warfarin for Ablation in Atrial Fibrillation.
N Engl J Med.
2017;376:1627-1636.
- Godier A, Dincq AS, Martin AC, Radu A, Leblanc I, Antona M, Vasse M,
Golmard JL, Mullier F, Gouin-Thibault I. Predictors of pre-procedural
concentrations of direct oral anticoagulants: a prospective
multicentre study. Eur Heart J.
2017;38:2431-2439.
- Sairaku A, Nakano Y, Onohara Y, Hironobe N, Matsumura H, Shimizu W,
Kihara Y. Residual
anticoagulation activity in atrial fibrillation patients with
temporary interrupted direct oral anticoagulants: Comparisons across 4
drugs. Thromb Res.
2019;183:119-123.
- Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M.
Comparative safety
and effectiveness of direct oral anticoagulants in patients with
atrial fibrillation in clinical practice in Scotland. Br J Clin
Pharmacol. 2019;85:422-431.
- Silverio A, Di Maio M, Prota C, De Angelis E, Radano I, Citro R,
Carrizzo A, Ciccarelli M, Vecchione C, Capodanno D, Galasso G. Safety
and efficacy of non-vitamin K antagonist oral anticoagulants in
elderly patients with atrial fibrillation.
Eur Heart J Cardiovasc
Pharmacother. 2019 Dec 12. Online ahead of print.
- Lip GY, Nieuwlaat R, Pisters R,
Lane DA, Crijns HJ. Refining clinical risk stratification for
predicting stroke and thromboembolism in atrial fibrillation using a
novel risk factor-based approach: the euro heart survey on atrial
fibrillation. Chest. 2010;137:263-72.
- O’Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey
PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson
ED. The ORBIT bleeding score: a simple bedside score to assess
bleeding risk in atrial fibrillation.
Eur Heart J. 2015;36:3258-64.
- Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L,
Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N,
Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document
Group. The 2018 European Heart Rhythm Association Practical Guide on
the use of non-vitamin K antagonist oral anticoagulants in patients
with atrial fibrillation. Eur Heart J. 2018;39:1330-1393.
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M,
Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton
JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn
S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P,
Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J,
Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus
warfarin in patients with atrial fibrillation.
N Engl J Med. 2011;365:981-92.
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A,
Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D,
Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L;
RE-LY Steering Committee and Investigators. Dabigatran versus warfarin
in patients with atrial fibrillation.
N Engl J Med. 2009;361:1139-51.
- Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin
JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M,
Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ,
Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus
warfarin in patients with atrial fibrillation.
N Engl J Med. 2013;369:2093-104.
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt
G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini
JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med. 2011;365:883-91.
- Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S,
Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M;
J-ROCKET AF study investigators. Safety and efficacy of adjusted dose
of rivaroxaban in Japanese patients with non-valvular atrial
fibrillation: subanalysis of J-ROCKET AF for patients with moderate
renal impairment. Circ J.
2013;77:632-8.
- Farmakis D, Davlouros P, Giamouzis G, Giannakoulas G, Pipilis A,
Tsivgoulis G, Parissis J. Direct Oral Anticoagulants in Nonvalvular
Atrial Fibrillation: Practical Considerations on the Choice of Agent
and Dosing. Cardiology.
2018;140:126-132.
- Watanabe R, Sairaku A, Yoshida Y, Nanasato M, Kamiya H, Suzuki H,
Ogura Y, Aoyama Y, Maeda M, Ando M, Eguchi S, Inden Y, Kihara Y,
Murohara T. Head-to-head comparison of acute and chronic pulmonary
vein stenosis for cryoballoon versus radiofrequency ablation.
Pacing Clin Electrophysiol.
2018;41:376-382.
- Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton
R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy
M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi
CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M,
Fassini G, Tondo C, Schweikert RA, Natale A. Periprocedural stroke and
bleeding complications in patients undergoing catheter ablation of
atrial fibrillation with different anticoagulation management: results
from the Role of Coumadin in Preventing Thromboembolism in Atrial
Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE)
randomized trial. Circulation.
2014;129:2638-44.
- Ebner M, Birschmann I, Peter A, Spencer C, Härtig F, Kuhn J,
Blumenstock G, Zuern CS, Ziemann U, Poli S.
Point-of-care testing
for emergency assessment of coagulation in patients treated with
direct oral anticoagulants.
Crit Care. 2017;21:32.
- Martin AC, Kyheng M, Foissaud V, Duhamel A, Marijon E, Susen S, Godier
A. Activated Clotting Time Monitoring during Atrial Fibrillation
Catheter Ablation: Does the Anticoagulant Matter?
J Clin Med. 2020;9:350.
- Sairaku A, Nakano Y, Kihara Y. Does dabigatran interfere with
intraablation heparinization?
Thromb Res. 2014;134:742-3.
- Sairaku A, Onohara Y, Hironobe N, Matsumura H, Kihara Y, Nakano Y.
Remaining activity of temporary interrupted direct oral anticoagulants
and its impact on intra-ablation heparinization in patients with
atrial fibrillation: Comparisons across four drugs and two dose
regimens. J Cardiovasc
Electrophysiol. 2020 May 27. Online ahead of print.